- Conditions
- Facioscapulohumeral Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 7
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 362
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinal Muscular Atrophy, Charcot-Marie-Tooth Disease, Muscular Dystrophy, Spinal Muscular Atrophy With Respiratory Distress 1, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Disease, Peroneal Muscular Atrophy
- Interventions
- sample collection
- Other
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 3
- States / cities
- Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Tadalafil and Sildenafil
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 7 Years to 15 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes
- Interventions
- Exercise program, Ascorbic Acid (Vitamin C)
- Behavioral · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 30 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drisapersen
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 5 Years to 80 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- DMD-Associated Dilated Cardiomyopathy
- Interventions
- SRD-001
- Genetic
- Lead sponsor
- Sardocor Corp.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
- Biological
- Lead sponsor
- MED Institute Inc.
- Industry
- Eligibility
- 5 Years to 10 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Flower Mound, Texas
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Prednisolone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 1 Month to 30 Months · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Sacramento, California • Orlando, Florida • Chicago, Illinois + 3 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 100 participants
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- WVE-N531
- Drug
- Lead sponsor
- Wave Life Sciences USA, Inc.
- Industry
- Eligibility
- 4 Years to 18 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • Atlanta, Georgia
- Conditions
- Merosin Deficient Congenital Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Prothelia, Inc.
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lakewood, California
- Conditions
- FSHD - Facioscapulohumeral Muscular Dystrophy
- Interventions
- ULSC, Placebo
- Biological
- Lead sponsor
- Restem, LLC.
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Pamrevlumab
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
- Conditions
- Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier, Dystrophinopathy Female Carrier
- Interventions
- Not listed
- Lead sponsor
- The Duchenne Registry
- Other
- Eligibility
- Not listed
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2047
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- SGLT-2 inhibitor, SGLT2 inhibitor
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 8 Years to 18 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone 0.25 mg/kg/day, Vamorolone 0.75 mg/kg/day, Vamorolone 2.0 mg/kg/day, Vamorolone 6.0 mg/kg/day
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 6 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
- Conditions
- FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
- Interventions
- AOC 1020, Placebo
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
- Conditions
- Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3
- Interventions
- SRP-9004
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Norfolk, Virginia
- Conditions
- Duchenne's Muscular Dystrophy, Scoliosis
- Interventions
- Not listed
- Lead sponsor
- Children's Healthcare of Atlanta
- Other
- Eligibility
- 6 Years to 21 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- 6 Years to 18 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • St Louis, Missouri • Charlotte, North Carolina
- Conditions
- Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease
- Interventions
- ACE-083
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 19
- States / cities
- Orange, California • Sacramento, California • Aurora, Colorado + 16 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- rAAVrh74.MCK.GALGT2
- Biological
- Lead sponsor
- Kevin Flanigan
- Other
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio